FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats

Cells. 2022 May 9;11(9):1585. doi: 10.3390/cells11091585.

Abstract

The immunophilin FKBP51, the angiomotin AmotL2, and the scaffoldin IQGAP1 are overexpressed in many types of cancer, with the highest increase in leucocytes from patients undergoing oxaliplatin chemotherapy. Inflammation is involved in the pathogenesis of nephrotoxicity induced by platinum analogs. Cilastatin prevents renal damage caused by cisplatin. This functional and confocal microscopy study shows the renal focal-segmental expression of TNFα after cisplatin administration in rats, predominantly of tubular localization and mostly prevented by co-administration of cilastatin. FKBP51, AmotL2 and IQGAP1 protein expression increases slightly with cilastatin administration and to a much higher extent with cisplatin, in a cellular- and subcellular-specific manner. Kidney tubule cells expressing FKBP51 show either very low or no expression of TNFα, while cells expressing TNFα have low levels of FKBP51. AmotL2 and TNFα seem to colocalize and their expression is increased in tubular cells. IQGAP1 fluorescence increases with cilastatin, cisplatin and joint cilastatin-cisplatin treatment, and does not correlate with TNFα expression or localization. These data suggest a role for FKBP51, AmotL2 and IQGAP1 in cisplatin toxicity in kidney tubules and in the protective effect of cilastatin through inhibition of dehydropeptidase-I.

Keywords: AmotL2; FKBP51; IQGAP1; cisplatin toxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiomotins
  • Animals
  • Carrier Proteins / metabolism
  • Cilastatin* / metabolism
  • Cilastatin* / pharmacology
  • Cilastatin* / therapeutic use
  • Cisplatin* / metabolism
  • Cisplatin* / toxicity
  • Humans
  • Rats
  • Tumor Necrosis Factor-alpha / metabolism
  • ras GTPase-Activating Proteins / metabolism

Substances

  • AMOTL2 protein, human
  • Angiomotins
  • Carrier Proteins
  • IQ motif containing GTPase activating protein 1
  • Tumor Necrosis Factor-alpha
  • ras GTPase-Activating Proteins
  • Cilastatin
  • Cisplatin

Grants and funding

This research was funded by Spanish Ministry of Economy and Competitiveness Instituto de Salud Carlos III-Fondo de Investigación en Salud (grant numbers: PI17/00276, PI20/01577 and CI21/00111 cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) Funds from the European Commission, “A way of making Europe”), ISCIII-RICORS2040 (Kidney Disease, grant number RD21/0005/0029), Comunidad de Madrid (grant number S2017-BMD-3686 (CIFRA2-CM)), Fundación Senefro (Nephrology research grant SENEFRO 18/01), Fundación Mutua Madrileña (research grant 2020) to A.L., Gobierno de Canarias (cofounded by FEDER), grant number ProID2020010073), and grant Proyecto Puente al Plan Estatal 2018 by Universidad de La Laguna, to J.A., and grant number OA20/089 from the Fundación Mapfre Guanarteme, Canary Islands, Spain to M.M.